TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34807255

Group type: EXPERIMENTAL
Intervention: Conventional education plus VR videos
Number of subjects: 346

Group type: COMPARATOR
Intervention: Conventional education
Number of subjects: 346
Study: 34496147

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity exercise (74 ± 9% V˙ O2peak)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (52 ± 5% V˙ O2peak)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both exercise intensities
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 13
Study: 32302308

Group type: EXPERIMENTAL
Intervention: CETA
Number of subjects: 248

Group type: COMPARATOR
Intervention: TAU-Plus
Number of subjects: 248
Study: 32194098

Group type: EXPERIMENTAL
Intervention: 12-month structured peer-support lifestyle intervention program involving 15 group sessions and linked community activities
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1007
Study: 33550448

Group type: EXPERIMENTAL
Intervention: Lyophilized PRP
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 19
Study: 33742291

Group type: EXPERIMENTAL
Intervention: Common bile duct (CBD) stenting after ERCP
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic treatment without stenting (Control Group B)
Number of subjects: 40
Study: 33636145

Group type: EXPERIMENTAL
Intervention: Phenotype A (n=2667): 30-day mortality rate 2.5% (95% CI 1.4–4.3)
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Phenotype B (n=2667): 30-day mortality rate 30.5% (95% CI 28.5–32.6)
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Phenotype C (n=2667): 30-day mortality rate 60.7% (95% CI 53.7–67.2)
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: Internal validation cohort: Phenotype A: 5.3% (95% CI 3.4–8.1), Phenotype B: 31.3% (95% CI 28.5–34.2), Phenotype C: 59.5% (95% CI 48.8–69.3)
Number of subjects: 4035

Group type: EXPERIMENTAL
Intervention: External validation cohort: Phenotype A: 3.7% (95% CI 2.0–6.4), Phenotype B: 23.7% (95% CI 21.8–25.7), Phenotype C: 51.4% (95% CI 41.9–60.7)
Number of subjects: 4035
Study: 34153102

Group type: EXPERIMENTAL
Intervention: AmbIGeM system (intervention group)
Number of subjects: 3240

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit wards (post hoc analysis)
Number of subjects: 3240

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3240
Study: 33506805

Group type: EXPERIMENTAL
Intervention: Biological treatment (ACS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Biological treatment (PRP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical treatment (MT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mechanical treatment (TT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical treatment (LT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical treatment (CM)
Number of subjects: 90
Study: 35132029

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided GONB at the C2 vertebral level
Number of subjects: 32

Group type: COMPARATOR
Intervention: Landmark-based GONB with sham ultrasound at the superior nuchal line
Number of subjects: 32
Study: 34076382

Group type: EXPERIMENTAL
Intervention: 4% articaine using buccal infiltration
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine using inferior alveolar nerve block
Number of subjects: 100

Group type: COMPARATOR
Intervention: 4% articaine or 2% lidocaine
Number of subjects: 100
Study: 35476650

Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (120 or 240 μg, with or without aluminum hydroxide)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (with aluminum hydroxide)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: RSVpreF vaccine (without aluminum hydroxide)
Number of subjects: 406
Study: 34172080

Group type: EXPERIMENTAL
Intervention: Word cloud generation based on PwCM experience
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Implementation plan for AO Spine RECODE‐DCM PSP surveys
Number of subjects: 79
Study: 36141773

Group type: EXPERIMENTAL
Intervention: Lentils
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trahana
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Halva
Number of subjects: 12

Group type: COMPARATOR
Intervention: Glucose (reference food)
Number of subjects: 12
Study: 32907393

Group type: EXPERIMENTAL
Intervention: Augmented arm rehabilitation (27 additional hours over six weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Supported self-management
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Augmented arm rehabilitation starting within nine weeks post-stroke
Number of subjects: 22
Study: 36410835

Group type: EXPERIMENTAL
Intervention: Higher intensity intervention (clinicians received 50 min communication skills training)
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Lower intensity intervention (clinicians did not receive additional communication skills training)
Number of subjects: 1599

Group type: EXPERIMENTAL
Intervention: Higher intensity intervention
Number of subjects: 1599

Group type: COMPARATOR
Intervention: Lower intensity intervention
Number of subjects: 1599
Study: 32819894

Group type: COMPARATOR
Intervention: Slowly expanding/evolving lesions
Number of subjects: 299

Group type: COMPARATOR
Intervention: Non-slowly expanding/evolving lesions
Number of subjects: 299
Study: 33429741

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 0
Study: 32100301

Group type: EXPERIMENTAL
Intervention: Health education on prevention of hand eczema
Number of subjects: 423

Group type: COMPARATOR
Intervention: Control group (172 MWAs)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Other factors (smoking, FLG mutations)
Number of subjects: 423
Study: 35662486

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.2 mg bolus via PCA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morphine (2 mg bolus via PCA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 41
Study: 34073414

Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Human rhino virus (HRV)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Viral co-detections
Number of subjects: 719

Group type: COMPARATOR
Intervention: Absence of RSV
Number of subjects: 719

Group type: COMPARATOR
Intervention: Coronavirus infection
Number of subjects: 719
Study: 32460989

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 30
Study: 32524889

Group type: EXPERIMENTAL
Intervention: Dynamic Exercise Program (DEP)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Dynamic Exercise Program (DEP) and Mediterranean Diet (MD)
Number of subjects: 106
Study: 33317377

Group type: EXPERIMENTAL
Intervention: Nursing care interventions based on Integrative Nursing and the Omaha System, including group-based activities (sightseeing, picnics, theater, cinema, group education, and charity activities) for 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard care, details not specified.
Number of subjects: 0
Study: 33478712

Group type: EXPERIMENTAL
Intervention: Antibacterial envelope
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Control (no antibacterial envelope)
Number of subjects: 6800
Study: 34264344

Group type: EXPERIMENTAL
Intervention: Real-time ultrasonography
Number of subjects: 75

Group type: COMPARATOR
Intervention: Static ultrasonography
Number of subjects: 75
Study: 34016357

Group type: COMPARATOR
Intervention: HA-LOW (fixed and low-intensity training sessions)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HA-HIT (RPE-regulated intermittent training sessions)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HA-LOW and HA-HIT
Number of subjects: 17
Study: 32345654

Group type: EXPERIMENTAL
Intervention: Genetic risk score (162 variants) for adult type 2 diabetes
Number of subjects: 4761

Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization (MR)
Number of subjects: 4761
Study: 35856777

Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg daily
Number of subjects: 6147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6147
Study: 33463734

Group type: EXPERIMENTAL
Intervention: Targeted liver US (Group A)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Complete upper abdominal scan (Group B)
Number of subjects: 465
Study: 32182680

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 66
Study: 36441136

Group type: EXPERIMENTAL
Intervention: CR + WL (Cardiac Rehabilitation plus Weight Loss program)
Number of subjects: 38

Group type: COMPARATOR
Intervention: CR (Cardiac Rehabilitation alone)
Number of subjects: 38
Study: 32919400

Group type: EXPERIMENTAL
Intervention: Active NeuroStar TMS monotherapy (n=48)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham TMS (n=55)
Number of subjects: 103
Study: 32020373

Group type: EXPERIMENTAL
Intervention: Perseus anesthesia workstation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fabius Plus anesthesia workstation
Number of subjects: 50
Study: 34284615

Group type: EXPERIMENTAL
Intervention: Pulsed mode SWD
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Continuous mode SWD
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 34324042

Group type: EXPERIMENTAL
Intervention: 10 mg/kg TXA
Number of subjects: 100

Group type: COMPARATOR
Intervention: 10 ml/kg normal saline (placebo)
Number of subjects: 100
Study: 35233880

Group type: EXPERIMENTAL
Intervention: PartnerCARE intervention (N = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist-control group (N = 30)
Number of subjects: 60
Study: 33351522

Group type: EXPERIMENTAL
Intervention: WeChat educational video
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 36195819

Group type: EXPERIMENTAL
Intervention: Patient transport to melanoma clinic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health system costs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Out-of-pocket costs and productivity losses
Number of subjects: 0
Study: 34370573

Group type: EXPERIMENTAL
Intervention: Taniborbactam (62.5 to 1,500 mg single doses; 250 to 750 mg every 8 hours for 10 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taniborbactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33080795

Group type: EXPERIMENTAL
Intervention: Higher blood levels of iron
Number of subjects: 310999

Group type: EXPERIMENTAL
Intervention: Higher blood levels of copper
Number of subjects: 310999
Study: 33883475

Group type: EXPERIMENTAL
Intervention: Basic psychological needs and upper limb factors
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Basic psychological needs
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Motivation regulations
Number of subjects: 236
Study: 32949787

Group type: EXPERIMENTAL
Intervention: SRP followed by aPDT (aPDT group)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: SRP followed by single subgingival application of 1.2 % simvastatin gel (SMV group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: SRP alone (SRP group)
Number of subjects: 11
Study: 36407430

Group type: EXPERIMENTAL
Intervention: DCB combined with cutting balloon
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cutting balloon angioplasty
Number of subjects: 140
Study: 36456006

Group type: EXPERIMENTAL
Intervention: Standardised heart team protocol
Number of subjects: 84

Group type: COMPARATOR
Intervention: Guideline‐based protocol
Number of subjects: 84
Study: 32546013

Group type: EXPERIMENTAL
Intervention: mild traumatic brain injury (mTBI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: concussion
Number of subjects: 81
Study: 32032829

Group type: EXPERIMENTAL
Intervention: Peer-mediated intervention for children with autism
Number of subjects: 71
Study: 35594542

Group type: EXPERIMENTAL
Intervention: Dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 5532

Group type: COMPARATOR
Intervention: Control group from COMPASS trial
Number of subjects: 5532
Study: 32124499

Group type: EXPERIMENTAL
Intervention: Peer-led cognitive behavioral training (CBT) intervention; 8 sessions over 1 year; delivered in the context of diabetes self-management.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Attention control arm; peer-delivered 8-session general health education program.
Number of subjects: 230
Study: 33303011

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination with routine MMR (M-M-R VaxPro)
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo (solvent only)
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Both groups (MMR and placebo)
Number of subjects: 6500
Study: 34366204

Group type: EXPERIMENTAL
Intervention: Peer recovery specialist (PRS) support
Number of subjects: 76

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 76
Study: 32546117

Group type: EXPERIMENTAL
Intervention: Ensemble methods (random forest, adaptive boosting, extremely randomized trees) for QSAR model design and prediction.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: y-scrambling method for model validation.
Number of subjects: 0
Study: 35362694

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) combined with a home-based exercise program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 26
Study: 33692028

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 104

Group type: COMPARATOR
Intervention: Initially undetectable pEBV DNA
Number of subjects: 104
Study: 36342781

Group type: EXPERIMENTAL
Intervention: Video decision aid
Number of subjects: 182

Group type: COMPARATOR
Intervention: Verbal narratives accompanied by photos
Number of subjects: 182
Study: 34605378

Group type: EXPERIMENTAL
Intervention: Social network sites (SNSs) training
Number of subjects: 144

Group type: COMPARATOR
Intervention: Lifestyle education (active control)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 144
Study: 32115853

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 35447283

Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by pre-operative chemotherapy (EXP)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Chemoradiotherapy and optional post-operative chemotherapy (STD)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Chemoradiotherapy and optional post-operative chemotherapy (STD+)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Chemoradiotherapy without post-operative chemotherapy (STD-)
Number of subjects: 574
Study: 33754435

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biodentine®
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Atmospheric pressure cold plasma (APCP)
Number of subjects: 240
Study: 34221478

Group type: EXPERIMENTAL
Intervention: Parental knowledge regarding antibiotic use for URTIs
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Parental beliefs about antibiotic effectiveness
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Parental practices regarding antibiotic prescriptions
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Parental attitudes towards physician prescribing
Number of subjects: 384
Study: 32007541

Group type: EXPERIMENTAL
Intervention: Colonoscopy after negative FIT results
Number of subjects: 96804
Study: 33807296

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 32396966

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) with 10% tape tension
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham (no tape tension)
Number of subjects: 66
Study: 36336697

Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Self-reported data
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Self-report and accelerometry data
Number of subjects: 430
Study: 32996559

Group type: EXPERIMENTAL
Intervention: Nutritional, inflammatory, hormonal and muscle biomarkers
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Glutamate, hydroxyproline, tau-methylhistidine levels, and sex
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Age-adjusted model including sex and 3 amino-acids
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Age-adjusted model including sex, hydroxyproline, and Charlson Comorbidity Index
Number of subjects: 193
Study: 35172876

Group type: EXPERIMENTAL
Intervention: Sterile water injections (6 injections of sterile water, 0.1-0.3 ml per injection)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% solution (placebo, 0.1-0.3 ml per injection)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Sterile water injections
Number of subjects: 154
Study: 34500174

Group type: EXPERIMENTAL
Intervention: 30 hours of auditory-based targeted cognitive training (TCT) + treatment-as-usual (TAU)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 42
Study: 35020047

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + episodic future thinking (EFT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) + episodic future thinking (EFT) + contingency management
Number of subjects: 72
Study: 32044190

Group type: EXPERIMENTAL
Intervention: Peer coaching intervention
Number of subjects: 55
Study: 34159869

Group type: EXPERIMENTAL
Intervention: Storytelling structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magic structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agent-based computational model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-blind control studies
Number of subjects: 0
Study: 33585998

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 32668087

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) plus placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Sertraline plus enhanced medication management
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: PE plus sertraline
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (trauma-exposed veterans without PTSD)
Number of subjects: 64
Study: 32820619

Group type: EXPERIMENTAL
Intervention: Single-dose apararenone (3.75-640 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Multiple-dose apararenone (10-40 mg/day on days 1-14, 320 mg loading dose on day 1 + 10 mg/day on days 2-14, or 40-320 mg loading dose on day 1 + 2.5-20 mg/day on days 2-14)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Single-dose apararenone (5-320 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Single-dose apararenone (160 or 640 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Eplerenone (200 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Fludrocortisone challenge
Number of subjects: 223
Study: 32600078

Group type: EXPERIMENTAL
Intervention: Myocardial damage group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-myocardial damage group
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Age >70 years old
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CRP >100 mg/L
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase >300 U/L
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lactic acid >3 mmol/L
Number of subjects: 82
Study: 34404473

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 311

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 311
Study: 32896753

Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard breast cancer treatment
Number of subjects: 32
Study: 36404704

Group type: EXPERIMENTAL
Intervention: Human threat agency
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Human temporal agency
Number of subjects: 449

Group type: COMPARATOR
Intervention: Bacteria threat agency
Number of subjects: 449

Group type: COMPARATOR
Intervention: Antibiotic resistance condition
Number of subjects: 449
Study: 34370941

Group type: EXPERIMENTAL
Intervention: Empowerment program conducted across 6 sessions
Number of subjects: 80
Study: 34244715

Group type: EXPERIMENTAL
Intervention: Incisional negative-pressure wound therapy (iNPWT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard dressing with suction drain
Number of subjects: 85
Study: 34371907

Group type: COMPARATOR
Intervention: 1 cup of espresso coffee/day (1C)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 3 cups of espresso coffee/day (3C)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 1 cup of espresso coffee plus two cocoa-based products containing coffee (PC) twice per day for 1 month
Number of subjects: 21
Study: 32686440

Group type: EXPERIMENTAL
Intervention: Mediterranean pattern diet (diet M)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Standard hypocaloric diet (diet C)
Number of subjects: 363
Study: 34373957

Group type: EXPERIMENTAL
Intervention: Zoledronate
Number of subjects: 710

Group type: COMPARATOR
Intervention: Denosumab
Number of subjects: 710
Study: 34391875

Group type: EXPERIMENTAL
Intervention: Test-1 (TRIOS 3/3Shape)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test-2 (Virtuo Vivo/Dental Wings)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Impregum/3M Espe)
Number of subjects: 20
Study: 35771315

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus ropivacaine (25 mL of 0.3% ropivacaine + 1 μg/kg dexmedetomidine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine (25 mL of 0.3% ropivacaine)
Number of subjects: 60